Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment.
Sun-Ho LeeMargaret WalsheEun Hye OhSung Wook HwangSang Hyoung ParkDong-Hoon YangJeong-Sik ByeonSeung-Jae MyungSuk-Kyun YangTomer GreenerAdam V WeizmanMark S SilverbergByong Duk YePublished in: Inflammatory bowel diseases (2022)
Change in serum albumin within the first 2 weeks of anti-TNF treatment is predictive of PNR, endoscopic outcomes, time-to-colectomy, and anti-TNF failure in patients with UC. Timely access to this biomarker enables early identification of patients with UC at risk of anti-TNF failure and may guide early optimization of anti-TNF treatment to improve disease outcomes.